Leerink Partners Maintains Outperform on Oruka Therapeutics, Raises Price Target to $86

Benzinga Newsdesk www.benzinga.com Positive 90.6%

Neg 0% Neu 0% Pos 90.6%

Leerink Partners analyst David Risinger maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $58 to $86.